Related Experiment Videos
The pharmacokinetics of ezetimibe
Chantale Simard1, Jacques Turgeon
1Université de Montréal, Québec.
Summary
Ezetimibe, a novel cholesterol absorption inhibitor, works by blocking intestinal cholesterol reabsorption. Its extensive glucuronidation and enterohepatic recirculation enhance its action, though elimination may be slower in elderly or renally impaired patients.
Area of Science:
- Pharmacology
- Gastroenterology
- Biochemistry
Background:
- Ezetimibe represents a new class of drugs targeting cholesterol absorption.
- It functions by inhibiting a specific intestinal membrane transporter responsible for cholesterol reabsorption.
Purpose of the Study:
- To elucidate the pharmacokinetic profile and metabolic pathways of ezetimibe.
- To investigate the impact of enterohepatic recirculation and patient factors on ezetimibe disposition.
Main Methods:
- Pharmacokinetic analysis of ezetimibe and its glucuronide metabolite following oral administration.
- Assessment of drug metabolism, focusing on glucuronidation and lack of cytochrome P450 involvement.
- Evaluation of ezetimibe's absorption, distribution, and elimination characteristics.
Main Results:
- Ezetimibe absorption is rapid and unaffected by food.
- The drug undergoes extensive intestinal glucuronidation; ezetimibe glucuronide is the primary circulating form.
- Enterohepatic recirculation prolongs intestinal residence time.
- Impaired elimination of ezetimibe glucuronide observed in elderly and renally insufficient patients, leading to 1.5-2 fold increased plasma concentrations.
- No significant drug interactions noted.
Conclusions:
- Ezetimibe's unique mechanism and pharmacokinetic properties, including extensive glucuronidation and enterohepatic recirculation, contribute to its efficacy.
- Special consideration for ezetimibe dosing may be warranted in elderly and renally impaired populations due to altered elimination.
- Ezetimibe exhibits a favorable drug interaction profile.